Hudson Bay Capital Management LP Kura Oncology, Inc. Transaction History

Hudson Bay Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$7.58 - $14.38 $568,500 - $1.08 Million	75,000 New	75,000 $1.08 Million
Q1 2023 May 15, 2023	BUY	$10.71 - $14.6 $2.2 Million - $2.99 Million	205,000 New	205,000 $2.51 Million
Q1 2022 May 16, 2022	SELL	$11.78 - $16.98 $137,024 - $197,511	-11,632 Reduced 20.54%	45,000 $724,000
Q4 2021 Feb 14, 2022	SELL	$12.22 - $19.57 $591,056 - $946,561	-48,368 Reduced 46.06%	56,632 $793,000
Q3 2021 Nov 15, 2021	BUY	$15.42 - $21.72 $385,500 - $543,000	25,000 Added 31.25%	105,000 $1.97 Million
Q2 2021 Aug 16, 2021	BUY	$20.85 - $29.88 $1.67 Million - $2.39 Million	80,000 New	80,000 $1.67 Million
Q4 2018 Feb 13, 2019	SELL	$10.6 - $17.49 $1.01 Million - $1.66 Million	-95,103 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$16.65 - $21.85 $417,964 - $548,500	25,103 Added 35.86%	95,103 $1.66 Million
Q2 2018 Aug 13, 2018	BUY	$14.8 - $18.8 $296,000 - $376,000	20,000 Added 40.0%	70,000 $1.27 Million
Q1 2018 May 14, 2018	BUY	$14.5 - $23.4 $725,000 - $1.17 Million	50,000 New	50,000 $938,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $603M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.